Lv41
660 积分 2025-01-15 加入
The Blood–Brain Barrier (BBB) Score
9天前
已完结
Pharmacological targeting of the JAK–STAT pathway: new concepts and emerging indications
10天前
已完结
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
21天前
已完结
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
29天前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
29天前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
29天前
已完结
The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy
1个月前
已完结
A structural basis for amylin receptor phenotype
1个月前
已完结
Structural insight into selectivity of amylin and calcitonin receptor agonists
1个月前
已完结
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
1个月前
已完结
皖公网安备34019202002308
